Research

Booster critical as COVID-19 vaccine-induced antibodies wane in 6 months, don't protect against omicron

A new study using serum from human blood samples suggests neutralizing antibody levels produced by two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against the omicron variant.

Fighting COVID-19 with milk?

As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science®, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to investigate the antiviral properties of cow milk protein against variants of SARS-CoV-2, the virus behind the illness.

Healthy gut microbiome improves success of cancer treatment

The largest study to date has confirmed the link between the gut microbiome and the response to cancer immunotherapy therapy for melanoma.

The study is published today in Nature Medicine and co-ordinated by King’s College London, CIBIO Department of the University of Trento and European Institute of Oncology in Italy, University of Groningen in the Netherlands and funded by the Seerave Foundation.

Repurposing FDA-approved drugs may help combat COVID-19

Several FDA-approved drugs - including for type 2 diabetes, hepatitis C and HIV - significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells.

Scientists uncover a new approach for treating aggressive cancer

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme.

Autoimmune diseases: discovery of central building block in immune cells

Autoimmune diseases are triggered when the immune system malfunctions and attacks the body's own structures. Although there is not, as yet, any cure for such diseases, their progression can be slowed down by therapeutic measures. Researchers at MedUni Vienna's Center for Physiology and Pharmacology have now discovered a central signaling pathway in immune cells that may help in the development of a new therapeutic approach.

Why natural killer cells react to COVID-19

Little has been known to date about how the immune system's natural killer (NK) cells detect which cells have been infected with SARS-CoV-2. An international team of scientist led by researchers from Karolinska Institutet in Sweden now shows that NK cells respond to a certain peptide on the surface of infected cells.

Booster critical as COVID-19 vaccine-induced antibodies wane in 6 months, don't protect against omicron

Fighting COVID-19 with milk?

Healthy gut microbiome improves success of cancer treatment

Repurposing FDA-approved drugs may help combat COVID-19

Scientists uncover a new approach for treating aggressive cancer

Autoimmune diseases: discovery of central building block in immune cells

Why natural killer cells react to COVID-19

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs